Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pathway Intermediates Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct art unit, reflecting a specific area of technical interest for the company. The portfolio's active prosecution involves 1 distinct examiner, indicating a very focused and low-volume prosecution period that centralizes the company's current interactions with the patent office.
KEVIN STEPHEN MARTIN is the busiest examiner for the company, with 1 pending office action currently under review. This 1 pending office action represents the total pending workload for Pathway Intermediates Limited, as there are no other pending office actions across the portfolio. With only 1 distinct examiner and 1 distinct art unit involved, the company's immediate patent outcomes are highly concentrated. This suggests that the practitioner's focus is entirely on a matter within the Biotechnology & Pharmaceuticals sector, rather than managing a broad array of diverse applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291631 | NOVEL APPLICATIONS FOR OXAZABOROLIDINES AND NEW METHODS OF MANUFACTURE THEREOF | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291631 | NOVEL APPLICATIONS FOR OXAZABOROLIDINES AND NEW METHODS OF MANUFACTURE THEREOF | MARTIN, KEVIN STEPHEN | 1624 | — | Final Rejection | — | Pending | Jan 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPathway Intermediates Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kevin Stephen Martin has the most, with 1 of Pathway Intermediates Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
